4.2 Review

Treatment of Chronic Migraine

Journal

CURRENT PAIN AND HEADACHE REPORTS
Volume 15, Issue 1, Pages 64-69

Publisher

SPRINGER
DOI: 10.1007/s11916-010-0159-x

Keywords

Chronic migraine; Treatment; Topiramate; Botulinum toxin

Funding

  1. German Research Council
  2. German Ministry of Education and Science
  3. European Union
  4. Allergan
  5. Almirall
  6. AstraZeneca
  7. Bayer
  8. GlaxoSmithKline
  9. Janssen-Cilag
  10. Pfizer
  11. Addex Pharmaceuticals
  12. Bayer Vital
  13. Berlin-Chemie AG
  14. Coherex Medical
  15. CoLucid Pharmaceuticals
  16. Boehringer Ingelheim
  17. Minster Pharmaceuticals
  18. MSD Pharmaceuticals
  19. Novartis AG
  20. Johnson Johnson
  21. Sanofi-Aventis
  22. Sanofi-Aventis and Medtronic
  23. BristolMyersSquibb
  24. Johnson & Johnson, Laboratories
  25. Medtronic
  26. St. Jude Medical
  27. Advanced Neurostimulation Systems

Ask authors/readers for more resources

Chronic migraine is defined in different ways. The most commonly used definition is headache on more than 15 days per month in patients with migraine. Chronic migraine is difficult to treat and requires a multidisciplinary approach. Only two pharmacological treatments have been shown to be effective in placebo-controlled randomized trials: topiramate and local injection of botulinum toxin. Both therapies are effective in patients with chronic migraine with and without medication overuse. Many other substances have been investigated in chronic daily headache. All trials were underpowered and, therefore, recommendations concerning possible efficacy are not possible.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available